Revolution Medicines director plans 15,080-share sale
Revolution Medicines director Elizabeth Anderson filed a Rule 144 notice to sell 15,080 shares, valued at $2.91M, over three months. The shares will be acquired via cash exercise of stock options and sold via Morgan Stanley Smith Barney LLC, with a stated sale date of September 22, 2026, on NASDAQ.
How this was made
The 30-second read
Why it matters
The disclosed sale represents a modest increase in share supply, unlikely to move the stock significantly unless combined with other negative news.
Market read
Primary insider sale filing with limited market impact.
What to watch
Potential upcoming catalyst could amplify impact if the market perceives the sale negatively.
Background
Form 144 filings disclose planned insider sales under Rule 144, providing transparency to investors.
Ticker impact
Director Elizabeth Anderson filed a Form 144 to sell up to 15,080 shares worth about $2.9 M over the next three months.
Minor downward pressure in the short term.
The sale size is relatively small for the market cap; impact limited to short‑term supply increase.
Market effects
None significant for biotech sector.
Limited to US market participants.
Low
Counterpoint
The sale may be a routine liquidity move and not indicative of insider concern.
Key entities
- DirectorElizabeth Anderson
Director of Revolution Medicines filing the sale.
- BrokerMorgan Stanley Smith Barney LLC
Broker handling the transaction.
